| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $141K | +48.3% | +44.7% |
| SG&A Expense | $1.2M | +64.0% | +950.4% |
| Operating Income | -$1.4M | -62.2% | -24.4% |
| Net Income | -$7.4M | +11.3% | -404.8% |
| EPS (Basic) | -$1.24 | -0.8% | -217.9% |
| EPS (Diluted) | -$1.24 | -0.8% | -217.9% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.4M | +16.9% | -26.1% |
| Short-term Investments | $201K | -23.2% | — |
| Current Assets | $23.0M | +20.5% | +7.9% |
| Total Assets | $56.0M | +24.1% | +1.6% |
| Current Liabilities | $1.6M | +48.7% | -67.0% |
| Total Liabilities | $19.4M | +1178.7% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.0M | -49.1% | — |
| Investing Cash Flow | -$3.0M | — | — |
| Financing Cash Flow | $6.2M | — | — |
| +66.8% |
| Stockholders' Equity | $35.2M | -19.2% | -18.9% |